1
|
Barale M, Oderda M, Faletti R, Falcone M, Pisano F, Marra G, Cassenti A, Delsedime L, Pacchioni D, Gontero P. The strange case of a hematocele mistaken for a neoplastic scrotal mass. Can Urol Assoc J 2015; 9:E217-9. [PMID: 26085884 DOI: 10.5489/cuaj.2630] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Hematoceles are usually associated with a history of scrotal trauma, are usually painful and rarely have an idiopathic origin. We describe the peculiar case of a hematocele mistaken for a testicular cancer.
Collapse
Affiliation(s)
- Maurizio Barale
- Department of Urology, University of Turin, Città della Salute e della Scienza, Torino, Italy
| | - Marco Oderda
- Department of Urology, University of Turin, Città della Salute e della Scienza, Torino, Italy
| | - Riccardo Faletti
- Department of Radiology, University of Turin, Città della Salute e della Scienza, Torino, Italy
| | - Marco Falcone
- Department of Urology, University of Turin, Città della Salute e della Scienza, Torino, Italy
| | - Francesca Pisano
- Department of Urology, University of Turin, Città della Salute e della Scienza, Torino, Italy
| | - Giancarlo Marra
- Department of Urology, University of Turin, Città della Salute e della Scienza, Torino, Italy
| | - Adele Cassenti
- Department of Medical Sciences, University of Turin, Torino, Italy
| | - Luisa Delsedime
- Department of Medical Sciences, University of Turin, Torino, Italy
| | | | - Paolo Gontero
- Department of Urology, University of Turin, Città della Salute e della Scienza, Torino, Italy
| |
Collapse
|
2
|
Samman M, Wood HM, Conway C, Stead L, Daly C, Chalkley R, Berri S, Senguven B, Ross L, Egan P, Chengot P, Ong TK, Pentenero M, Gandolfo S, Cassenti A, Cassoni P, Al Ajlan A, Samkari A, Barrett W, MacLennan K, High A, Rabbitts P. A novel genomic signature reclassifies an oral cancer subtype. Int J Cancer 2015; 137:2364-73. [PMID: 26014678 DOI: 10.1002/ijc.29615] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2015] [Accepted: 05/15/2015] [Indexed: 12/22/2022]
Abstract
Verrucous carcinoma of the oral cavity (OVC) is considered a subtype of classical oral squamous cell carcinoma (OSCC). Diagnosis is problematic, and additional biomarkers are needed to better stratify patients. To investigate their molecular signature, we performed low-coverage copy number (CN) sequencing on 57 OVC and exome and RNA sequencing on a subset of these and compared the data to the same OSCC parameters. CN results showed that OVC lacked any of the classical OSCC patterns such as gain of 3q and loss of 3p and demonstrated considerably fewer genomic rearrangements compared to the OSCC cohort. OVC and OSCC samples could be clearly differentiated. Exome sequencing showed that OVC samples lacked mutations in genes commonly associated with OSCC (TP53, NOTCH1, NOTCH2, CDKN2A and FAT1). RNA sequencing identified genes that were differentially expressed between the groups. In silico functional analysis showed that the mutated and differentially expressed genes in OVC samples were involved in cell adhesion and keratinocyte proliferation, while those in the OSCC cohort were enriched for cell death and apoptosis pathways. This is the largest and most detailed genomic and transcriptomic analysis yet performed on this tumour type, which, as an example of non-metastatic cancer, may shed light on the nature of metastases. These three independent investigations consistently show substantial differences between the cohorts. Taken together, they lead to the conclusion that OVC is not a subtype of OSCC, but should be classified as a distinct entity.
Collapse
Affiliation(s)
- Manar Samman
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom.,Pathology and Clinical Laboratory Department, King Fahad Medical City, Riyadh, Saudi Arabia
| | - Henry M Wood
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom
| | - Caroline Conway
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom
| | - Lucy Stead
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom
| | - Catherine Daly
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom
| | - Rebecca Chalkley
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom
| | - Stefano Berri
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom
| | - Burcu Senguven
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom
| | - Lisa Ross
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom
| | - Philip Egan
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom
| | - Preetha Chengot
- St James's Institute of Oncology, St James's University Hospital, Leeds, United Kingdom
| | - Thian K Ong
- Leeds Dental Institute, Leeds General Infirmary, Leeds, United Kingdom
| | - Monica Pentenero
- Oral Medicine and Oral Oncology Unit, Department of Oncology, University of Torino, Turin, Italy
| | - Sergio Gandolfo
- Oral Medicine and Oral Oncology Unit, Department of Oncology, University of Torino, Turin, Italy
| | - Adele Cassenti
- Pathology Unit, Department of Medical Sciences, University of Torino, Turin, Italy
| | - Paola Cassoni
- Pathology Unit, Department of Medical Sciences, University of Torino, Turin, Italy
| | | | - Alaa Samkari
- National Guard Health Affairs, Riyadh, Saudi Arabia
| | | | - Kenneth MacLennan
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom.,St James's Institute of Oncology, St James's University Hospital, Leeds, United Kingdom
| | - Alec High
- St James's Institute of Oncology, St James's University Hospital, Leeds, United Kingdom.,Leeds Dental Institute, Leeds General Infirmary, Leeds, United Kingdom
| | - Pamela Rabbitts
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom
| |
Collapse
|
3
|
Senetta R, Duregon E, Sonetto C, Spadi R, Mistrangelo M, Racca P, Chiusa L, Munoz FH, Ricardi U, Arezzo A, Cassenti A, Castellano I, Papotti M, Morino M, Risio M, Cassoni P. YKL-40/c-Met expression in rectal cancer biopsies predicts tumor regression following neoadjuvant chemoradiotherapy: a multi-institutional study. PLoS One 2015; 10:e0123759. [PMID: 25875173 PMCID: PMC4398550 DOI: 10.1371/journal.pone.0123759] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2014] [Accepted: 01/21/2015] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Neoadjuvant chemo-radiotherapy (CRT) followed by surgical resection is the standard treatment for locally advanced rectal cancer, although complete tumor pathological regression is achieved in only up to 30% of cases. A clinicopathological and molecular predictive stratification of patients with advanced rectal cancer is still lacking. Here, c-Met and YKL-40 have been studied as putative predictors of CRT response in rectal cancer, due to their reported involvement in chemoradioresistance in various solid tumors. MATERIAL AND METHODS A multicentric study was designed to assess the role of c-Met and YKL-40 expression in predicting chemoradioresistance and to correlate clinical and pathological features with CRT response. Immunohistochemistry and fluorescent in situ hybridization for c-Met were performed on 81 rectal cancer biopsies from patients with locally advanced rectal adenocarcinoma. All patients underwent standard (50.4 gy in 28 fractions + concurrent capecitabine 825 mg/m2) neoadjuvant CRT or the XELOXART protocol. CRT response was documented on surgical resection specimens and recorded as tumor regression grade (TRG) according to the Mandard criteria. RESULTS A significant correlation between c-Met and YKL-40 expression was observed (R = 0.43). The expressions of c-Met and YKL-40 were both significantly associated with a lack of complete response (86% and 87% of c-Met and YKL-40 positive cases, p< 0.01 and p = 0.006, respectively). Thirty of the 32 biopsies co-expressing both markers had partial or absent tumor response (TRG 2-5), strengthening their positive predictive value (94%). The exclusive predictive role of YKL-40 and c-Met was confirmed using a multivariate analysis (p = 0.004 and p = 0.007 for YKL-40 and c-Met, respectively). TRG was the sole morphological parameter associated with poor outcome. CONCLUSION c-Met and YKL-40 expression is a reliable predictor of partial/absent response to neoadjuvant CRT in rectal cancer. Targeted therapy protocols could take advantage of prior evaluations of c-MET and YKL-40 expression levels to increase therapeutic efficacy.
Collapse
Affiliation(s)
- Rebecca Senetta
- Department of Medical Sciences, University of Turin, Turin, Italy
| | | | - Cristina Sonetto
- SSCVD Colorectal Cancer Unit, City of Health and Science Hospital of Turin, Turin, Italy
| | - Rossella Spadi
- SSCVD Colorectal Cancer Unit, City of Health and Science Hospital of Turin, Turin, Italy
| | - Massimiliano Mistrangelo
- Digestive and Colorectal Surgery, Centre of Minimal Invasive Surgery, University of Turin, Turin, Italy
| | - Patrizia Racca
- SSCVD Colorectal Cancer Unit, City of Health and Science Hospital of Turin, Turin, Italy
| | - Luigi Chiusa
- Department of Medical Sciences, University of Turin, Turin, Italy
| | | | | | - Alberto Arezzo
- Digestive and Colorectal Surgery, Centre of Minimal Invasive Surgery, University of Turin, Turin, Italy
| | - Adele Cassenti
- Department of Medical Sciences, University of Turin, Turin, Italy
| | | | - Mauro Papotti
- Department of Oncology, University of Turin, Turin, Italy
| | - Mario Morino
- Digestive and Colorectal Surgery, Centre of Minimal Invasive Surgery, University of Turin, Turin, Italy
| | - Mauro Risio
- Candiolo Cancer Institute—FPO (Fondazione del Piemonte per l'0ncologia), IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), Candiolo, Turin, Italy
| | - Paola Cassoni
- Department of Medical Sciences, University of Turin, Turin, Italy
- * E-mail:
| |
Collapse
|
4
|
Isella C, Terrasi A, Bellomo SE, Petti C, Galatola G, Muratore A, Mellano A, Senetta R, Cassenti A, Sonetto C, Inghirami G, Trusolino L, Fekete Z, De Ridder M, Cassoni P, Storme G, Bertotti A, Medico E. Stromal contribution to the colorectal cancer transcriptome. Nat Genet 2015; 47:312-9. [PMID: 25706627 DOI: 10.1038/ng.3224] [Citation(s) in RCA: 439] [Impact Index Per Article: 48.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2014] [Accepted: 01/28/2015] [Indexed: 12/19/2022]
Abstract
Recent studies identified a poor-prognosis stem/serrated/mesenchymal (SSM) transcriptional subtype of colorectal cancer (CRC). We noted that genes upregulated in this subtype are also prominently expressed by stromal cells, suggesting that SSM transcripts could derive from stromal rather than epithelial cancer cells. To test this hypothesis, we analyzed CRC expression data from patient-derived xenografts, where mouse stroma supports human cancer cells. Species-specific expression analysis showed that the mRNA levels of SSM genes were mostly due to stromal expression. Transcriptional signatures built to specifically report the abundance of cancer-associated fibroblasts (CAFs), leukocytes or endothelial cells all had significantly higher expression in human CRC samples of the SSM subtype. High expression of the CAF signature was associated with poor prognosis in untreated CRC, and joint high expression of the stromal signatures predicted resistance to radiotherapy in rectal cancer. These data show that the distinctive transcriptional and clinical features of the SSM subtype can be ascribed to its particularly abundant stromal component.
Collapse
Affiliation(s)
- Claudio Isella
- 1] Candiolo Cancer Institute, Fondazione Piemontese per l'Oncologia'Istituto di Ricovero e Cura a Carattere Scientifico (FRO-IRCCS), Candiolo, Italy. [2] Department of Oncology, University of Torino, Candiolo, Italy
| | - Andrea Terrasi
- Department of Oncology, University of Torino, Candiolo, Italy
| | - Sara Erika Bellomo
- 1] Candiolo Cancer Institute, Fondazione Piemontese per l'Oncologia'Istituto di Ricovero e Cura a Carattere Scientifico (FRO-IRCCS), Candiolo, Italy. [2] Department of Oncology, University of Torino, Candiolo, Italy
| | - Consalvo Petti
- Candiolo Cancer Institute, Fondazione Piemontese per l'Oncologia'Istituto di Ricovero e Cura a Carattere Scientifico (FRO-IRCCS), Candiolo, Italy
| | - Giovanni Galatola
- Candiolo Cancer Institute, Fondazione Piemontese per l'Oncologia'Istituto di Ricovero e Cura a Carattere Scientifico (FRO-IRCCS), Candiolo, Italy
| | - Andrea Muratore
- Candiolo Cancer Institute, Fondazione Piemontese per l'Oncologia'Istituto di Ricovero e Cura a Carattere Scientifico (FRO-IRCCS), Candiolo, Italy
| | - Alfredo Mellano
- Candiolo Cancer Institute, Fondazione Piemontese per l'Oncologia'Istituto di Ricovero e Cura a Carattere Scientifico (FRO-IRCCS), Candiolo, Italy
| | - Rebecca Senetta
- Department of Medical Science, University of Torino, Torino, Italy
| | - Adele Cassenti
- Department of Medical Science, University of Torino, Torino, Italy
| | | | - Giorgio Inghirami
- Department of Molecular Biotechnology and Health Science, Center for Experimental Research and Medical Studies, University of Torino, Torino, Italy
| | - Livio Trusolino
- 1] Candiolo Cancer Institute, Fondazione Piemontese per l'Oncologia'Istituto di Ricovero e Cura a Carattere Scientifico (FRO-IRCCS), Candiolo, Italy. [2] Department of Oncology, University of Torino, Candiolo, Italy
| | - Zsolt Fekete
- Institute of Oncology Prof. Dr. Ion Chiricuta, Cluj, Romania
| | - Mark De Ridder
- Department of Radiotherapy, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium
| | - Paola Cassoni
- Department of Medical Science, University of Torino, Torino, Italy
| | - Guy Storme
- Department of Radiotherapy, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium
| | - Andrea Bertotti
- 1] Candiolo Cancer Institute, Fondazione Piemontese per l'Oncologia'Istituto di Ricovero e Cura a Carattere Scientifico (FRO-IRCCS), Candiolo, Italy. [2] Department of Oncology, University of Torino, Candiolo, Italy
| | - Enzo Medico
- 1] Candiolo Cancer Institute, Fondazione Piemontese per l'Oncologia'Istituto di Ricovero e Cura a Carattere Scientifico (FRO-IRCCS), Candiolo, Italy. [2] Department of Oncology, University of Torino, Candiolo, Italy
| |
Collapse
|
5
|
Duregon E, Cassenti A, Pittaro A, Ventura L, Senetta R, Rudà R, Cassoni P. Better see to better agree: phosphohistone H3 increases interobserver agreement in mitotic count for meningioma grading and imposes new specific thresholds. Neuro Oncol 2015; 17:663-9. [PMID: 25646026 DOI: 10.1093/neuonc/nov002] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2014] [Accepted: 12/30/2014] [Indexed: 12/25/2022] Open
Abstract
BACKGROUND Mitotic count on hematoxylin and eosin (H&E)-stained slides is a crucial diagnostic criterion in meningioma grading. However, mitosis assessment on H&E slides can be impaired by technical factors and by pathologist's experience. Phosphohistone H3 (PHH3) serine-10 is a mitosis-specific antibody that has proven to facilitate mitotic count in various tumors. METHODS A series of 70 meningiomas (15 grade I, 40 grade II, 15 grade III) was used to validate PHH3 intra- and interobserver reproducibility and to identify PHH3-specific mitotic thresholds. Four pathologists with different experience in neuropathology counted mitoses on both H&E- and PHH3-stained slides. RESULTS H&E and PHH3 mitotic rates were highly correlated (Pearson's r = 0.92, P < .0001). PHH3 mitotic counts had both a good mean interobserver correlation (R(m) = 0.83) and a good intraclass correlation (0.78), higher than H&E mitotic indices (R(m) = 0.77, intraclass correlation = 0.71). After further stratification of meningiomas according to World Health Organization grade, PHH3 performed better in terms of interobserver concordance (Kendall's W = 0.761) compared with H&E (Kendall's W = 0.697). Referring to the same meningioma groups identified by World Health Organization grade as the gold standard, the volume under the receiver operator characteristic surface was 0.91, indicating a very good diagnostic ability of PHH3 scores in discriminating the 3 meningioma groups. The 2 optimal PHH3-specific cutoff values were 6.61 and 22.02. CONCLUSION PHH3 staining is a useful diagnostic complementary tool to standard H&E mitotic count, optimizing intra- and interobserver reproducibility. PHH3-specific mitotic thresholds should be adopted to avoid overgrading of meningioma when ancillary methods are employed.
Collapse
Affiliation(s)
- Eleonora Duregon
- Department of Medical Sciences, University of Torino, Turin, Italy (A.C., A.P., R.S., P.C.); Department of Oncology, University of Torino at San Luigi Hospital, Orbassano, Italy (E.D.); Department of Statistical Sciences, University of Padua, Padova, Italy (L.V.); Department of Neuro-Oncology, University and City of Health and Science Hospital of Turin, Turin, Italy (R.R.)
| | - Adele Cassenti
- Department of Medical Sciences, University of Torino, Turin, Italy (A.C., A.P., R.S., P.C.); Department of Oncology, University of Torino at San Luigi Hospital, Orbassano, Italy (E.D.); Department of Statistical Sciences, University of Padua, Padova, Italy (L.V.); Department of Neuro-Oncology, University and City of Health and Science Hospital of Turin, Turin, Italy (R.R.)
| | - Alessandra Pittaro
- Department of Medical Sciences, University of Torino, Turin, Italy (A.C., A.P., R.S., P.C.); Department of Oncology, University of Torino at San Luigi Hospital, Orbassano, Italy (E.D.); Department of Statistical Sciences, University of Padua, Padova, Italy (L.V.); Department of Neuro-Oncology, University and City of Health and Science Hospital of Turin, Turin, Italy (R.R.)
| | - Laura Ventura
- Department of Medical Sciences, University of Torino, Turin, Italy (A.C., A.P., R.S., P.C.); Department of Oncology, University of Torino at San Luigi Hospital, Orbassano, Italy (E.D.); Department of Statistical Sciences, University of Padua, Padova, Italy (L.V.); Department of Neuro-Oncology, University and City of Health and Science Hospital of Turin, Turin, Italy (R.R.)
| | - Rebecca Senetta
- Department of Medical Sciences, University of Torino, Turin, Italy (A.C., A.P., R.S., P.C.); Department of Oncology, University of Torino at San Luigi Hospital, Orbassano, Italy (E.D.); Department of Statistical Sciences, University of Padua, Padova, Italy (L.V.); Department of Neuro-Oncology, University and City of Health and Science Hospital of Turin, Turin, Italy (R.R.)
| | - Roberta Rudà
- Department of Medical Sciences, University of Torino, Turin, Italy (A.C., A.P., R.S., P.C.); Department of Oncology, University of Torino at San Luigi Hospital, Orbassano, Italy (E.D.); Department of Statistical Sciences, University of Padua, Padova, Italy (L.V.); Department of Neuro-Oncology, University and City of Health and Science Hospital of Turin, Turin, Italy (R.R.)
| | - Paola Cassoni
- Department of Medical Sciences, University of Torino, Turin, Italy (A.C., A.P., R.S., P.C.); Department of Oncology, University of Torino at San Luigi Hospital, Orbassano, Italy (E.D.); Department of Statistical Sciences, University of Padua, Padova, Italy (L.V.); Department of Neuro-Oncology, University and City of Health and Science Hospital of Turin, Turin, Italy (R.R.)
| |
Collapse
|
6
|
Stacchini A, Pacchioni D, Demurtas A, Aliberti S, Cassenti A, Isolato G, Gazzera C, Veltri A, Sapino A, Papotti M, Freddi M, Palestini N, Sisto G, Novero D. Utilility of flow cytometry as ancillary study to improve the cytologic diagnosis of thyroid lymphomas. Cytometry 2014; 88:320-9. [DOI: 10.1002/cyto.b.21204] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/14/2014] [Revised: 10/10/2014] [Accepted: 11/06/2014] [Indexed: 12/30/2022]
Affiliation(s)
- Alessandra Stacchini
- Diagnostic Laboratory Department; Flow Cytometry Unit, Citta' della Salute e della Scienza; Turin Italy
| | - Donatella Pacchioni
- Diagnostic Laboratory Department; Pathology Service, Citta' della Salute e della Scienza; Turin Italy
| | - Anna Demurtas
- Diagnostic Laboratory Department; Flow Cytometry Unit, Citta' della Salute e della Scienza; Turin Italy
| | - Sabrina Aliberti
- Diagnostic Laboratory Department; Flow Cytometry Unit, Citta' della Salute e della Scienza; Turin Italy
| | - Adele Cassenti
- Diagnostic Laboratory Department; Pathology Service, Citta' della Salute e della Scienza; Turin Italy
| | - Giuseppe Isolato
- Diagnostic Imaging Department; Citta' della Salute e della Scienza; Turin Italy
| | - Carlo Gazzera
- Diagnostic Imaging Department; Citta' della Salute e della Scienza; Turin Italy
| | - Andrea Veltri
- Department of Clinical and Biomedical Sciences; University of Turin at San Luigi Hospital; Orbassano Turin Italy
| | - Anna Sapino
- Diagnostic Laboratory Department; Pathology Service, Citta' della Salute e della Scienza; Turin Italy
| | - Mauro Papotti
- Department of Clinical and Biomedical Sciences; University of Turin at San Luigi Hospital; Orbassano Turin Italy
| | - Milena Freddi
- Surgery Department; Citta' della Salute e della Scienza; Turin Italy
| | - Nicola Palestini
- Surgery Department; Citta' della Salute e della Scienza; Turin Italy
| | - Gabriella Sisto
- Surgery Department; Citta' della Salute e della Scienza; Turin Italy
| | - Domenico Novero
- Diagnostic Laboratory Department; Pathology Service, Citta' della Salute e della Scienza; Turin Italy
| |
Collapse
|
7
|
Caltabiano R, Barbagallo GMV, Castaing M, Cassenti A, Senetta R, Cassoni P, Albanese V, Lanzafame S. Prognostic value of EGFR expression in de novo and progressed atypical and anaplastic meningiomas: an immunohistochemical and fluorescence in situ hybridization pilot study. J Neurosurg Sci 2013; 57:139-151. [PMID: 23486338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
AIM The aim of this study was to assess both the epidermal growth factor receptor (EGFR) protein expression by immunohistochemistry and the EGFR gene amplification by fluorescence in situ hybridization in meningiomas of different grade, in order to evaluate their possible role in the development of the disease. EGFR protein belongs to the family of tyrosine kinase growth factor receptors, which also includes HER2, HER3 and HER4. Elevated expression or activity of EGFR has been reported in several cancers, including brain tumours. EGFR activation can enhance the malignant potential of epithelial tissues. METHODS We investigated whether there was a difference in the EGFR protein expression and the EGFR gene amplification between the so called de novo malignant meningiomas and recurrent meningiomas with or without malignant progression from a previously lower grade tumor. Our goal was to evaluate if EGFR expression was a useful marker to select patients affected by meningioma with a major risk of recurrences. We also assessed the prognostic value of the EGFR expression on overall survival. RESULTS Progression from benign meningiomas to atypical or anaplastic meningiomas correlated with an increase in the expression of EGFR protein. Our study shows that EGFR immunostaining in meningiomas directly correlates to the tumor's grade. The EGFR expression did not correlate with the overall survival and the recurrence-free survival of the patients affected by meningioma (de novo, recurrent and progressed). CONCLUSION We submit that the EGFR expression is not a useful prognostic element to identify patients with a major risk of meningioma recurrence.
Collapse
Affiliation(s)
- R Caltabiano
- G.F. Ingrassia Department, University of Catania, Catania, Italy
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Stella GM, Senetta R, Cassenti A, Ronco M, Cassoni P. Cancers of unknown primary origin: current perspectives and future therapeutic strategies. J Transl Med 2012; 10:12. [PMID: 22272606 PMCID: PMC3315427 DOI: 10.1186/1479-5876-10-12] [Citation(s) in RCA: 71] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2011] [Accepted: 01/24/2012] [Indexed: 12/22/2022] Open
Abstract
It is widely accepted that systemic neoplastic spread is a late event in tumour progression. However, sometimes, rapidly invasive cancers are diagnosed because of appearance of metastatic lesions in absence of a clearly detectable primary mass. This kind of disease is referred to as cancer of unknown primary (CUP) origin and accounts for 3-5% of all cancer diagnosis. There is poor consensus on the extent of diagnostic and pathologic evaluations required for these enigmatic cases which still lack effective treatment. Although technology to predict the primary tumour site of origin is improving rapidly, the key issue is concerning the biology which drives early occult metastatic spreading. This review provides the state of the art about clinical and therapeutic management of this malignant syndrome; main interest is addressed to the most recent improvements in CUP molecular biology and pathology, which will lead to successful tailored therapeutic options.
Collapse
Affiliation(s)
- Giulia Maria Stella
- Department of Oncological Sciences, Institute for Cancer Research and Treatment (IRCC), Candiolo (Turin), Italy.
| | | | | | | | | |
Collapse
|